These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20966414)

  • 1. Functional occurrence of the interaction of tissue plasminogen activator with the NR1 Subunit of N-methyl-D-aspartate receptors during stroke.
    Macrez R; Bezin L; Le Mauff B; Ali C; Vivien D
    Stroke; 2010 Dec; 41(12):2950-5. PubMed ID: 20966414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis.
    Macrez R; Obiang P; Gauberti M; Roussel B; Baron A; Parcq J; Cassé F; Hommet Y; Orset C; Agin V; Bezin L; Berrocoso TG; Petersen KU; Montaner J; Maubert E; Vivien D; Ali C
    Stroke; 2011 Aug; 42(8):2315-22. PubMed ID: 21680906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity.
    Lopez-Atalaya JP; Roussel BD; Levrat D; Parcq J; Nicole O; Hommet Y; Benchenane K; Castel H; Leprince J; To Van D; Bureau R; Rault S; Vaudry H; Petersen KU; Santos JS; Ali C; Vivien D
    J Cereb Blood Flow Metab; 2008 Jun; 28(6):1212-21. PubMed ID: 18334994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.
    Armstead WM; Riley J; Yarovoi S; Higazi AA; Cines DB
    Stroke; 2016 Aug; 47(8):2096-102. PubMed ID: 27354223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
    Wang L; Fan W; Cai P; Fan M; Zhu X; Dai Y; Sun C; Cheng Y; Zheng P; Zhao BQ
    Ann Neurol; 2013 Feb; 73(2):189-98. PubMed ID: 23280993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory.
    Benchenane K; Castel H; Boulouard M; Bluthé R; Fernandez-Monreal M; Roussel BD; Lopez-Atalaya JP; Butt-Gueulle S; Agin V; Maubert E; Dantzer R; Touzani O; Dauphin F; Vivien D; Ali C
    J Cell Sci; 2007 Feb; 120(Pt 4):578-85. PubMed ID: 17244650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13.
    Fan M; Xu H; Wang L; Luo H; Zhu X; Cai P; Wei L; Lu L; Cao Y; Ye R; Fan W; Zhao BQ
    Sci Rep; 2016 May; 6():25971. PubMed ID: 27181025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.
    Reddrop C; Moldrich RX; Beart PM; Farso M; Liberatore GT; Howells DW; Petersen KU; Schleuning WD; Medcalf RL
    Stroke; 2005 Jun; 36(6):1241-6. PubMed ID: 15879331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.
    Samson AL; Nevin ST; Croucher D; Niego B; Daniel PB; Weiss TW; Moreno E; Monard D; Lawrence DA; Medcalf RL
    J Neurochem; 2008 Nov; 107(4):1091-101. PubMed ID: 18796005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-D-aspartate glutamate receptors improves hemorrhagic stroke outcome.
    Gaberel T; Macrez R; Gauberti M; Montagne A; Hebert M; Petersen KU; Touze E; Agin V; Emery E; Ali C; Vivien D
    Neuropharmacology; 2013 Apr; 67():267-71. PubMed ID: 23219658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke.
    Merino-Zamorano C; Hernández-Guillamon M; Jullienne A; Le Béhot A; Bardou I; Parés M; Fernández-Cadenas I; Giralt D; Carrera C; Ribó M; Vivien D; Ali C; Rosell A; Montaner J
    Stroke; 2015 Feb; 46(2):477-84. PubMed ID: 25503547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurotoxicity of tissue plasminogen activator?
    Kaur J; Zhao Z; Klein GM; Lo EH; Buchan AM
    J Cereb Blood Flow Metab; 2004 Sep; 24(9):945-63. PubMed ID: 15356416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke.
    Durand A; Chauveau F; Cho TH; Kallus C; Wagner M; Boutitie F; Maucort-Boulch D; Berthezène Y; Wiart M; Nighoghossian N
    Cerebrovasc Dis; 2014; 38(4):268-75. PubMed ID: 25401979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.
    Fernández-Monreal M; López-Atalaya JP; Benchenane K; Cacquevel M; Dulin F; Le Caer JP; Rossier J; Jarrige AC; Mackenzie ET; Colloc'h N; Ali C; Vivien D
    J Biol Chem; 2004 Dec; 279(49):50850-6. PubMed ID: 15448144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
    Kilic E; Kilic U; Matter CM; Lüscher TF; Bassetti CL; Hermann DM
    Stroke; 2005 Feb; 36(2):332-6. PubMed ID: 15625301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine improves safety of thrombolysis for stroke.
    Montagne A; Hébert M; Jullienne A; Lesept F; Le Béhot A; Louessard M; Gauberti M; Orset C; Ali C; Agin V; Maubert E; Vivien D
    Stroke; 2012 Oct; 43(10):2774-81. PubMed ID: 22879098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator.
    Roussel BD; Mysiorek C; Rouhiainen A; Jullienne A; Parcq J; Hommet Y; Culot M; Berezowski V; Cecchelli R; Rauvala H; Vivien D; Ali C
    J Cell Sci; 2011 Jun; 124(Pt 12):2070-6. PubMed ID: 21610098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
    Copin JC; Bengualid DJ; Da Silva RF; Kargiotis O; Schaller K; Gasche Y
    Eur J Neurosci; 2011 Oct; 34(7):1085-92. PubMed ID: 21895804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.